Biography
Julia Sichun Liu is an associate in Weil’s Mergers & Acquisitions practice and is based in New York. Julia participates in the representation of public and private companies in mergers, acquisitions and divestitures.
Julia has been part of the teams advising:
- TPG Pace Solutions Corp., a SPAC sponsored by TPG Pace Group, in its $4.5 billion business combination with Vacasa LLC
- Sanofi in its $1.9 billion acquisition of Kadmon Holdings, Inc. and its approximately $2.2 billion acquisition of Inhibrx, Inc.
- American Securities LLC in its $1.85 billion sale of its portfolio company ASP Acuren Holdings Inc. to Admiral Acquisition Limited
- Special Committee of Black Knight, Inc. in the $1.2 billion acquisition of all of the equity interests Black Knight did not already own in Optimal Blue
- Elevate Brands LLC in its acquisition by SellerX
- Ember SPV I Purchaser Inc. (an entity controlled by funds managed by Ember Infrastructure Management, LP) in its acquisition, alongside IQ and CDPQ, of H2O Innovation Inc.
- Steward Health Care System LLC, the largest private, physician-owned for-profit healthcare network in the United States with over $9 billion in funded debt obligations, in connection with the sale of its assets
- General Atlantic, as equity sponsor and lender in connection with the chapter 11 cases of beauty brand company FORMA Brands
Julia joined Weil as a summer associate in 2020. While in law school, she served as a judicial intern to the Honorable Sidney H. Stein of the U.S. District Court for the Southern District of New York.
Julia received her J.D., cum laude, from the University of Michigan Law School, where she served as the Editor-in-Chief of the Michigan Business & Entrepreneurial Law Review, and her B.A., with distinction and Phi Beta Kappa, from Cornell University. She is a native Mandarin speaker.
Firm News & Announcements
Firm News & Announcements
- Weil Advises Sanofi in its Acquisition of Inhibrx, Inc. Deal Brief — January 23, 2024
- Weil Advises Churchill Capital VII in its $1.58B Combination with CorpAcq Deal Brief — August 01, 2023